<DOC>
	<DOCNO>NCT00628680</DOCNO>
	<brief_summary>The purpose study determine AAT-023 ( Zuragen ) solution superior Heparin prevent Catheter Related Blood Stream Infections End Stage Renal Disease patient .</brief_summary>
	<brief_title>A Multi-Centered , Two-Arm , Randomized Study Comparing Effects AAT-023 ( Zuragen ) Solution , Heparin Incidence Catheter Related Blood Stream Infections Tunneled Chronic Central Venous Catheters Dialysis</brief_title>
	<detailed_description>The purpose study show AAT-023 ( Zuragen ) Solution superior Heparin prevent Catheter Related Blood Stream Infections ( CRBSI ) use catheter lock solution Central Venous Catheter 's Dialysis hemodialysis treatment ( 3x per week ) , CRBSI 's defined concordant bacteria find catheter peripheral blood exit site peripheral blood subject demonstrate temperature great 38 degree celcius .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . End Stage Renal Disease 18 yr old . 2 . CVCD average dialysis flow rate 300 mL/min three recent visit . 3 . Expectation Investigator CVCD may need 26 week . 4 . Dialysis catheter three type ) single body single entry exit , b ) single body split end , c ) twin catheter one catheter removal blood another return . 5 . Kt/V &gt; 1.1 equivalent URR 6 . Negative serum pregnancy unless surgically sterile post menopausal &gt; 1yr . 7 . Negative blood culture result preenrollment blood sample draw . 8 . Ability patient sign understand inform consent . 9 . Most recent lab result n't indicate hypocalcemia ( &lt; 7mg/dL ) thrombocytopenia ( &lt; 20,000 ) 10 . Avg . systolic blood pressure &gt; 90 mmHg measure recent three dialysis treatment . 11 . Lack sign current blood stream infection begin prior three dialysis treatment . 1 . A known Heparin allergy history type 2 ( antibody mediate ) Heparininduced thrombocytopenia . 2 . Active bleeding site document positive stool hemocult test within 28 day enrollment study . 3 . Bloodstream infection , exit site infection infection require antibiotic use within 14 day enrollment antibiotic list section 4.2.3 within 30 day enrollment Vancomycin antibiotic list section 4.2.3 protocol 4 . Inability comply condition , complete protocol opinion Investigator . 5 . Pregnant breast feeding . 6 . Documented allergy sodium citrate , methylene blue , methyl/paraben and/or propyl paraben . 7 . Documented chronic intrinsic coagulopathy evidence persistently significantly elevate Prothrombin ( INR &gt; 3 ) , Partial Thromboplastin Time ( PTT &gt; 60 second ) , thrombocytopenia ( platlet count &lt; 20,000/mm ) . 8 . Malignancy require chemotherapy radiation treatment within 180 day enrollment . 9 . Documented requirement &gt; 5,000 unit Heparin per catheter lumen maintain catheter patency ( decrease blood flow demonstrate 5,000 unit per lumen Heparin catheter lock ) current catheter . 10 . Contraindications citrate take drug may interact citrate . 11 . Documented history glucose6phosphate dehydrogenase deficiency ( G6PD Druginduced methemoglobinemia ) . 12 . Participation another research study . 13 . Comorbidities , HIV , active hepatitis recent transplant , opinion Investigator , may increase risk associate study participation may interfere interpretation study result would make subject inappropriate entry study . 14 . Unknown priming volume catheter lumens . 15 . Redness 1 cm diameter pu around catheter exit site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Renal Disease</keyword>
	<keyword>Kidney Failure</keyword>
	<keyword>End Stage Renal Disease</keyword>
</DOC>